Form 4: Marinus Pharmaceuticals CEO Scott Braunstein Receives Stock Options and Restricted Stock Units

Scott Braunstein, CEO of Marinus Pharmaceuticals, was granted stock options and restricted stock units (RSUs) on June 18, 2024, according to a recent SEC filing.

Summary

• On June 18, 2024, Scott Braunstein, the Chairman and CEO of Marinus Pharmaceuticals, received 37,300 restricted stock units (RSUs) and options to purchase 167,825 shares of common stock.
• The RSUs vest in full on July 15, 2025, contingent upon Braunstein's continued service with Marinus Pharmaceuticals.
• Each RSU represents the right to receive one share of Marinus Pharmaceuticals common stock.
• The stock options have an exercise price of $1.40 and also vest fully on July 15, 2025, subject to continued service.
• Following these transactions, Braunstein directly owns 310,812 shares of common stock and options to purchase 167,825 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of equity-based compensation is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicit negative indicators.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to drive long-term value creation.
• The vesting schedule, contingent on continued service, encourages the CEO's commitment to the company.

Industry Context

Stock options and RSU grants are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry.
• Companies like Biogen, Amgen, and Vertex Pharmaceuticals also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders: The grant of equity-based compensation can be viewed positively as it aligns management's interests with shareholder value.
• Employees: The CEO's incentivization can lead to improved company performance, benefiting employees.

Key Dates

Keywords

Marinus Pharmaceuticals, Scott Braunstein, SEC Form 4, Stock Options, Restricted Stock Units, RSUs, MRNS, Beneficial Ownership, Executive Compensation